Literature DB >> 26446737

Defining response to anti-VEGF therapies in neovascular AMD.

W M Amoaku, U Chakravarthy, R Gale, M Gavin, F Ghanchi, J Gibson, S Harding, R L Johnston, S P Kelly, A Lotery, S Mahmood, G Menon, S Sivaprasad, J Talks, A Tufail, Y Yang.   

Abstract

Entities:  

Year:  2015        PMID： 26446737      PMCID： PMC5176328          DOI： 10.1038/eye.2015.159

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  11 in total

1.  Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT.

Authors:  Cynthia A Toth; Vincent Tai; Maxwell Pistilli; Stephanie J Chiu; Katrina P Winter; Ebenezer Daniel; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying; Sina Farsiu; Maureen G Maguire
Journal:  Ophthalmol Retina       Date:  2018-12-03

2.  Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series.

Authors:  Geraldine R Slean; Kornwipa Hemarat; Rahul N Khurana; Jay M Stewart
Journal:  Int J Retina Vitreous       Date:  2016-01-25

Review 3.  Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.

Authors:  Chandrakumar Balaratnasingam; Elona Dhrami-Gavazi; Jesse T McCann; Quraish Ghadiali; K Bailey Freund
Journal:  Clin Ophthalmol       Date:  2015-12-17

4.  Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline.

Authors:  Sakiko Minami; Norihiro Nagai; Misa Suzuki; Toshihide Kurihara; Hideki Sonobe; Mamoru Kamoshita; Atsuro Uchida; Hajime Shinoda; Hitoshi Takagi; Shozo Sonoda; Taiji Sakamoto; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

5.  Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Authors:  Ahmed M Hagag; Shruti Chandra; Hagar Khalid; Ali Lamin; Pearse A Keane; Andrew J Lotery; Sobha Sivaprasad
Journal:  J Clin Med       Date:  2020-06-21       Impact factor: 4.241

6.  Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study.

Authors:  Imoro Zeba Braimah; Ernest Kenu; Kwesi N Amissah-Arthur; Stephen Akafo; Kwaku Oppong Kwarteng; Winfried M Amoaku
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

7.  miR-106b suppresses pathological retinal angiogenesis.

Authors:  Catherine Ménard; Ariel M Wilson; Agnieszka Dejda; Khalil Miloudi; François Binet; Sergio Crespo-Garcia; Célia Parinot; Frédérique Pilon; Rachel Juneau; Elisabeth Mma Andriessen; Gaëlle Mawambo; John Paul SanGiovanni; Vincent De Guire; Przemyslaw Sapieha
Journal:  Aging (Albany NY)       Date:  2020-12-23       Impact factor: 5.682

8.  Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials.

Authors:  Gui-Shuang Ying; Maureen G Maguire; Wei Pan; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Daniel F Martin
Journal:  Ophthalmol Retina       Date:  2018-06

9.  Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration.

Authors:  Murray H Brilliant; Kamyar Vaziri; Thomas B Connor; Stephen G Schwartz; Joseph J Carroll; Catherine A McCarty; Steven J Schrodi; Scott J Hebbring; Krishna S Kishor; Harry W Flynn; Andrew A Moshfeghi; Darius M Moshfeghi; M Elizabeth Fini; Brian S McKay
Journal:  Am J Med       Date:  2015-10-30       Impact factor: 4.965

10.  CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration.

Authors:  Taeyoung Koo; Sung Wook Park; Dong Hyun Jo; Daesik Kim; Jin Hyoung Kim; Hee-Yeon Cho; Jeungeun Kim; Jeong Hun Kim; Jin-Soo Kim
Journal:  Nat Commun       Date:  2018-05-10       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.